U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Invitrx Therapeutics, Inc - 514522 - 03/31/2020
  1. Warning Letters

CLOSEOUT LETTER

Invitrx Therapeutics, Inc MARCS-CMS 514522 —

Delivery Method:
United Parcel Service
Reference #:
17-17
Recipient:
Recipient Name
Mr. Habib Torfi
Recipient Title
CEO/President
Invitrx Therapeutics, Inc

20503 Crescent Bay Dr.
Lake Forest, CA 92630
United States

Issuing Office:
Office of Human and Animal Food Operations West Division 5

United States

Dear Mr. Doe:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter # 17-17, dated February 27, 2017. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Sergio Chavez, Compliance Branch Director
Office of Human and Animal Food Operations
West Division 5

Back to Top